keyword
MENU ▼
Read by QxMD icon Read
search

Infliximab

keyword
https://www.readbyqxmd.com/read/29140940/rapid-infliximab-infusion-in-children-with-inflammatory-bowel-disease-a-multicenter-north-american-experience
#1
Wael El-Matary, Dana M H Dykes, Laura Bauman, Abdul Elkadri, Matthew W Carroll, Marisa R Izaguirre, Jennifer deBruyn, Charles M Samson, Alisa Muniz Crim, Sabina Ali, Andrew Grossman
BACKGROUND: Infliximab (IFX) infusion may lead to development of anti-IFX antibodies, and subsequent infusion reactions (IRs). The safety of rapid IFX infusion administered over 60 minutes has been under-investigated in children with inflammatory bowel disease. In a multicenter study, the frequency and nature of rapid infusion-associated IRs were examined. METHODS: The medical records of all consecutive children with inflammatory bowel disease receiving rapid IFX infusions between January 2014 and December 2016 were reviewed...
December 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29140939/infliximab-therapeutic-drug-monitoring-changes-clinical-decisions-in-a-virtual-biologics-clinic-for-inflammatory-bowel-disease
#2
Christian P Selinger, Marco V Lenti, Tanya Clark, Helen Rafferty, David Gracie, Alexander C Ford, Anthony OʼConnor, Tariq Ahmad, P John Hamlin
BACKGROUND: Virtual biologics clinics are often used to review patients with inflammatory bowel disease receiving biological therapy, with decisions whether to continue, switch, or stop therapy made based on review of symptoms, disease history, and investigations. We aimed to investigate whether therapeutic drug monitoring of infliximab (IFX) trough levels and anti-drug antibodies influences decision making within a virtual biologics clinic. METHODS: For all patients with inflammatory bowel disease receiving IFX maintenance therapy, 2 decisions were recorded in a preset format...
December 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29139091/pharmacological-approach-to-the-management-of-crohn-s-disease-patients-with-perianal-disease
#3
REVIEW
Fernando Bermejo, Iván Guerra, Alicia Algaba, Antonio López-Sanromán
Perianal localization of Crohn's disease involves significant morbidity, affects quality of life and results in an increased use of healthcare resources. Medical and surgical therapies contribute to its management. The objective of this review is to address the current understanding in the management of perianal Crohn's disease, with the main focus in reviewing pharmacological therapies, including stem cells. In complex fistulas, once local sepsis has been controlled by surgical drainage and/or antibiotics, anti-TNF drugs (infliximab, adalimumab) are the first-line therapy, with or without associated immunomodulators...
November 14, 2017: Drugs
https://www.readbyqxmd.com/read/29130957/clinical-disease-patterns-in-a-regional-swiss-cohort-of-34-pyoderma-gangrenosum-patients
#4
Antonios G A Kolios, Alissa Gübeli, Barbara Meier, Julia-Tatjana Maul, Thomas Kündig, Jakob Nilsson, Jürg Hafner, Emmanuella Guenova, Katrin Kerl, Mark Anliker, Werner Kempf, Alexander A Navarini, Lars E French, Antonio Cozzio
BACKGROUND/AIM: Pyoderma gangrenosum (PG) is a rare, neutrophilic dermatosis often associated with an underlying disease, and clinical data or larger studies are rare. METHODS: In this retrospective study, disease characteristics, clinical manifestations, and treatment response were evaluated in a Swiss cohort of PG patients. RESULTS: In participating centers, 34 cases (21 females) of PG were analyzed based on clinical and histological presentation between 2002 and 2012...
November 7, 2017: Dermatology: International Journal for Clinical and Investigative Dermatology
https://www.readbyqxmd.com/read/29127626/impact-of-infliximab-and-etanercept-biosimilars-on-biological-disease-modifying-antirheumatic-drugs-utilisation-and-nhs-budget-in-the-uk
#5
Mohammed I Aladul, Raymond W Fitzpatrick, Stephen R Chapman
OBJECTIVE: Biological disease-modifying antirheumatic drugs (bDMARDs) are effective but expensive options for treating rheumatoid arthritis. The introduction of infliximab and etanercept biosimilars presents a significant potential cost saving in a financially constrained health system such as the National Health Service (NHS) in the UK. This study examines the impact of the introduction of infliximab and etanercept biosimilars on the utilisation of bDMARDs and subsequent budget impact...
November 10, 2017: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/29124994/a-review-on-biosimilar-infliximab-ct-p13-in-the-treatment-of-inflammatory-bowel-disease
#6
Klaudia Farkas, Tamás Molnár
The introduction of biological agents has led to significant changes in the treatment of inflammatory bowel disease (IBD). The relatively high price of infliximab (IFX) and the expiration of the patents led to the introduction of biosimilar agents. CT-P13 was the first IFX biosimilar approved in the same indications as the reference product; however, the approval was based on randomized clinical trials conducted in patients with rheumatoid arthritis and ankylosing spondylitis. In the past 2-3 years, new findings from prospective observational studies supported the short-, medium- and long-term clinical efficacy and safety of CT-P13 in patients with IBD...
November 10, 2017: Immunotherapy
https://www.readbyqxmd.com/read/29124774/early-drug-and-anti-infliximab-antibody-levels-for-prediction-of-primary-nonresponse-to-infliximab-therapy
#7
H Bar-Yoseph, N Levhar, L Selinger, U Manor, M Yavzori, O Picard, E Fudim, U Kopylov, R Eliakim, S Ben-Horin, Y Chowers, B Ungar
BACKGROUND: Primary nonresponse, defined as lack of clinical benefit during the induction phase, occurs in up to 30% of IBD patients treated with infliximab. The mechanisms underlying primary nonresponse have not yet been clearly defined. AIM: To evaluate the association of early (week 2 and week 6) induction infliximab and anti-infliximab antibody levels with primary nonresponse. METHODS: A retrospective observational case-control study of inflammatory bowel disease patients treated with infliximab and followed at Sheba Medical Center between 2009 and 2016 was performed...
November 9, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29123588/infliximab-treatment-in-a-paediatric-patient-with-ulcerative-colitis-who-developed-acute-pancreatitis-due-to-azathioprine-during-follow-up
#8
Ahmet Basturk, Aygen Yilmaz, Meryem Keceli, Reha Artan
No abstract text is available yet for this article.
2017: Przegla̜d Gastroenterologiczny
https://www.readbyqxmd.com/read/29123576/the-efficacy-and-safety-of-the-biosimilar-product-inflectra-%C3%A2-compared-to-the-reference-drug-remicade-%C3%A2-in-rescue-therapy-in-adult-patients-with-ulcerative-colitis
#9
Magdalena Kaniewska, Andrzej Moniuszko, Grażyna Rydzewska
Introduction: The biosimilar product Inflectra(®) has been approved by the European Medicine Agency (EMA) for the same indications as its reference drug, infliximab, based on studies in patients with rheumatic diseases. Thus far, there have not been enough data regarding its efficacy and safety in ulcerative colitis (UC). Aim: To assess the efficacy and safety of the biosimilar product Inflectra(®) in comparison with its reference biological agent (Remicade(®)) in rescue therapy in adult patients presenting with severe exacerbation of UC, as well as to evaluate recurrence rate during a 6-month observation after finish of treatment...
2017: Przegla̜d Gastroenterologiczny
https://www.readbyqxmd.com/read/29123438/intravitreal-infliximab-injection-to-treat-experimental-endophthalmitis
#10
Osman Ondas, Orhan Ates, Sadullah Keles, Kenan Yildirim, Orhan Baykal, Selina Aksak Karamese, Murat Karamese, Hakan Uslu, Mustafa Yildirim, Muhammet Emin Naldan, Irem Ates
Objective: The purpose of this study was to compare the use of an intravitreal injection of infliximab and of dexamethasone combined with vancomycin to treat experimental endophthalmitis induced by Staphylococcus epidermidis. Materials and Methods: The study was conducted between March 25 and April 13, 2012. Twenty-five six-month-old healthy rabbits were used, each weighing 2.5-3 kg. The rabbits were randomized into five groups with five animals per group. Endophthalmitis was induced by 0...
October 2017: Eurasian Journal of Medicine
https://www.readbyqxmd.com/read/29122286/integrated-microreactor-for-enzymatic-reaction-automation-an-easy-step-toward-the-quality-control-of-monoclonal-antibodies
#11
Yoann Ladner, Silvia Mas, Gaelle Coussot, Killian Bartley, Jérôme Montels, Jacques Morel, Catherine Perrin
The main purpose of the present work is to provide a fully integrated miniaturized electrophoretic methodology in order to facilitate the quality control of monoclonal antibodies (mAbs). This methodology called D-PES, which stands for Diffusion-mediated Proteolysis combined with an Electrophoretic Separation, permits to perform subsequently mAb tryptic digestion and electrophoresis separation of proteolysis products in an automated manner. Tryptic digestion conditions were optimized regarding the influence of enzyme concentration and incubation time in order to achieve similar enzymatic digestion efficiency to that obtained with the classical methodology (off-line)...
October 27, 2017: Journal of Chromatography. A
https://www.readbyqxmd.com/read/29121178/exploration-of-predictive-biomarkers-of-early-infliximab-response-in-acute-severe-colitis-a-prospective-pilot-study
#12
Lauren Beswick, Ourania Rosella, Gennaro Rosella, Belinda Headon, Miles P Sparrow, Peter R Gibson, Daniel R van Langenberg
Background: Outcomes of acute severe ulcerative colitis (ASUC) appear dependent on early intervention with the first and/or further infliximab(IFX) doses, though parameters to guide decision-making remain uncertain. Aim: To assess whether serum/faecal IFX levels and inflammatory biomarkers early post-IFX dose can predict ASUC outcomes. Methods: This prospective pilot study consecutively recruited inpatients with steroid-refractory ASUC, who then received 1-3 IFX rescue doses (5mg/kg/dose) per treating clinician's discretion...
November 7, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29121038/is-mean-platelet-volume-a-good-predictor-of-sustained-response-to-one-year-infliximab-therapy-in-pediatric-patients-with-crohn-s-disease
#13
Roma Herman, Małgorzata Sładek, Stanisław Pieczarkowski, Paulina Dumnicka, Krzysztof Fyderek
Over the past years, there is a growing number of newly diagnosed pediatric patients with Crohn's disease (CD). Severe course of CD often requires biological treatment with Infliximab (IFX). Loss of response to biological treatment is a major problem. Mean platelet volume (MPV) was reported as a good marker of sustained response to IFX therapy in adults. This study is to determine whether MPV measured prior to IFX therapy and a er its third dose can be used as a predictive marker of sustained response to biological therapy in children with severe course of CD...
2017: Folia Medica Cracoviensia
https://www.readbyqxmd.com/read/29119722/c-reactive-protein-as-a-predictor-of-low-trough-infliximab-concentrations-in-patients-who-lose-response-to-infliximab
#14
Marie P Boyle, Alan C Moss, Aoibhlinn M O'Toole, Byron Vaughn, Adam S Cheifetz
BACKGROUND: Low serum infliximab (IFX) concentrations are associated with an increased risk of loss of response in IBD. Whether C-reactive protein (CRP) could be used to identify patients with low drug concentrations is unknown. The objective of this study was to evaluate the test characteristics of CRP in identifying low serum IFX concentrations. METHODS: We measured serum IFX concentrations and CRP levels in patients who experienced symptom deterioration while on IFX (reactive cohort)...
November 9, 2017: Journal of Digestive Diseases
https://www.readbyqxmd.com/read/29115687/epidemiological-survey-from-2009-to-2012-of-psoriatic-patients-in-japanese-society-for-psoriasis-research
#15
Toshihiro Ito, Hidetoshi Takahashi, Akira Kawada, Hajime Iizuka, Hidemi Nakagawa
Since 1982, the Japanese Society for Psoriasis Research has conducted annual epidemiological surveys of patients with psoriasis. Kawada et al. have reported data for 1982-2001 and Takahashi et al. have reported data for 2002-2008. The present study evaluated 9290 psoriatic cases according to age and sex (2009-2012). The male : female ratio was 2.08:1 (6281 male patients [67.6%] to 3009 female patients [32.4%]). The most prevalent type was psoriasis vulgaris (85.6% of all cases), which was followed by psoriasis arthropathica (6...
November 8, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/29115101/holospinal-epidural-abscess-combined-with-multifocal-extraspinal-abscesses-in-an-elderly-patient-with-rheumatoid-arthritis-receiving-infliximab-therapy
#16
Ioannis D Siasios, Benjamin Szewczyk, Amanda Zakeri, Joseph M Kowalski, Vassilios G Dimopoulos
No abstract text is available yet for this article.
November 7, 2017: Journal of Neurosurgical Sciences
https://www.readbyqxmd.com/read/29110911/blau-syndrome-with-good-reponses-to-tocilizumab-a-case-report-and-focused-literature-review
#17
Li Lu, Min Shen, Dongbin Jiang, Yanmin Li, Xiaolong Zheng, Yao Li, Zhixun Li, Leilei Zhang, Jungen Tang, Yanke Guo, Shengyun Liu, Zhaohui Zheng, Guanmin Gao, Quancheng Kan
OBJECTIVES: Blau syndrome (BS), a rare auto-inflammatory granulomatous disease, is a progressive disorder. Usually the maintenance dose of glucocorticoid may not be tapered below 15 mg per day while immunosuppressives is used. There has been some experience with biologic agents in refractory BS patients. The objective of this study is to describe the case of a BS patient benefiting from Tocilizumab, a humanized monoclonal antibody against interleukin 6 receptor. METHODS: We report the first Chinese patient with BS who was resistant to currently available therapies but had rapid quiescence after using Tocilizumab...
September 25, 2017: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29109492/yes-we-are-still-talking-about-cylosporin-vs-infliximab-in-steroid-resistant-acute-severe-ulcerative-colitis
#18
Charles N Bernstein, Asher Kornbluth
The Spanish IBD Registry (ENEIDA) is reporting in this issue of the Journal on a retrospective assessment of outcomes of cyclosporine use and infliximab use to treat steroid refractory acute severe ulcerative colitis (SR-ASUC) between 1989 and 2013. Overall, they found similar outcomes in terms of 3 month and 1 year colectomy rates. Serious adverse events were lower in cyclosporine users. While this study does not meet the standard of a prospective randomized controlled trial, it does remind us that cyclosporine can be effective in (SR-ASUC) and should be considered in those who have already failed antibody to tumor necrosis factor therapy or as a bridge to immunomodulators that have a slower onset of action...
November 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/29104875/a-novel-system-for-the-quantification-of-the-adcc-activity-of-therapeutic-antibodies
#19
Christophe Lallemand, Feifei Liang, Flore Staub, Maud Simansour, Benoit Vallette, Lue Huang, Rosa Ferrando-Miguel, Michael G Tovey
Novel ADCC effector cells expressing the V-variant or F-variant of FcγRIIIa (CD16a) and firefly luciferase under the control of a chimeric promoter incorporating recognition sequences for the principal transcription factors involved in FcγRIIIa signal transduction, together with novel target cells overexpressing a constant high level of the specific antigen recognized by rituximab, trastuzumab, cetuximab, infliximab, adalimumab, or etanercept, confer improved sensitivity, specificity, and dynamic range in an ADCC assay relative to effector cells expressing a NFAT-regulated reporter gene and wild-type target cells...
2017: Journal of Immunology Research
https://www.readbyqxmd.com/read/29102156/systematic-switch-from-innovator-infliximab-to-biosimilar-infliximab-in-inflammatory-chronic-diseases-in-daily-clinical-practice-the-experience-of-cochin-university-hospital-paris-france
#20
Jérôme Avouac, Anna Moltó, Vered Abitbol, Adrien Etcheto, Axelle Salcion, Loriane Gutermann, Caroline Klotz, Muriel Elhai, Pascal Cohen, Pierre Antoine Soret, Florence Morin, Ornella Conort, François Chast, Claire Goulvestre, Claire Le Jeunne, Stanislas Chaussade, André Kahan, Christian Roux, Yannick Allanore, Maxime Dougados
OBJECTIVE: To investigate effectiveness of systematic switching treatment from innovator infliximab to biosimilar infliximab, and its associated factors. METHODS: In this prospective observational study, all adult patients receiving maintenance therapy with innovator infliximab in Cochin University Hospital were systematically switched to biosimilar infliximab. Effectiveness was assessed by the retention rate of biosimilar infliximab at the time of the third infusion...
October 5, 2017: Seminars in Arthritis and Rheumatism
keyword
keyword
1757
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"